Probiotics in Mild Alzheimer's Disease
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age65-85
SponsorUniversity of Nicosia
About this trial
The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).
Eligibility criteria
Qualifiers
Adults ≥65 years, able to give consent
Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)
approximately equal male:female ratio
Disqualifiers
Inability to give consent
other neurological disease
relevant psychiatric disorders (e.g. major depression)
gastrointestinal/metabolic conditions
Trial design
Treatments tested in this trial
- Probiotic Blend Capsule
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Nicosia
Lead sponsor
Cyprus Institute of Neurology and Genetics
Collaborator
Source ClinicalTrials.gov